Insulet Corporation (NASDAQ: PODD) is a global medical device company focused on transforming diabetes care through its proprietary tubeless insulin pump technology. The company's flagship product line, the Omnipod Insulin Management System, provides a discreet, wearable, and disposable alternative to traditional tube-based insulin pumps and multiple daily injections. The portfolio includes the Omnipod 5, the first FDA-cleared tubeless automated insulin delivery (AID) system that integrates with third-party continuous glucose monitors (CGMs) to automatically adjust insulin delivery. Insulet operates a "razor-and-blade" business model, generating recurring revenue from the ongoing sale of its disposable Pods, which provide up to three days of continuous insulin delivery.
Geographically, Insulet has a strong footprint in the United States, which accounts for the majority of its revenue, while also expanding its international presence across Europe, Canada, Australia, and the Middle East. Beyond diabetes care, the company leverages its Omnipod technology platform for the subcutaneous delivery of non-insulin drugs across other therapeutic areas. A notable example is its Drug Delivery segment, which supplies pods for Amgen's Neulasta Onpro kit used in post-chemotherapy treatment. Insulet's competitive position is bolstered by its user-friendly, smartphone-controlled technology, extensive intellectual property, and continuous innovation in the automated insulin delivery market.
